Breast Cancer Research and Treatment **34**: 289, 1995.

Author index, Volume 34

Akasofu K 35
Alonso MC 15
Amadori D 63
Avril A 119

Bajetta E 237
Bajorko P 63
Bartoli C 237
Bergman L 77
Boatman KK 161
Bonetti A 221
Bonetti F 221
Bonichon F 119
Bono A 237
Bontenbal M 183

Callegari M 237
Capelli P 221
Castelli P 221
Cetto GL 221
Chajès V 199
Chen D 97
Chetrite G 139
Climent MA 15
Coindre J-M 119
Collette HJA 55
Corgnati A 221

Daly RJ 85
de Mascarel I 119
de Waard F 129
de Wit R 183
De Paola F 63
Demers L 45
den Tonkelaar I 55,129
Devine PL 245
Di Leo A 237
Ding IYF 97
Durand M 119
Duroux MA 245
Dutrillaux B 25

El-Ashry D 97
Engler KS 265

Fay M 229
Ferrari L 237
Flamigni A 63
Fracheboud J 129
Fraher KM 71
Frassineti GL 63
Friedmann A 229

Gasperi-Campani A 63
Geng C-S 147
Gnant MFX 213
Grady LH 265
Grove R 45

Huper G 253

Iglehart JD 253

Jäger W 279
Jakesz R 213
Joy GJ 245

Kern FG 97
Kerns B-J 253
Klijn JGM 183
Kostner GM 199
Kruit WHJ 183

Labrie F 147
Lane DM 161
Lévesque C 147
Li S 147
Lindblom A 171
Liu Y 97
Llanos M 15
Locker GJ 213
López JJ 15

Mader RM 213
Magdelenat H 25
Manfrin E 221
Manni A 45
Marks JR 253
Martel J 45
Martignoni G 221
McConathy WJ 161
McGuckin MA 245
Memoli V 229
Micciolo R 221
Miceli R 237
Milandri C 63
Moglia D 237
Molino A 221

Nguyen B-L 139
Nishida E 35
North WG 229
Nortilli R 221

Ojeda B 15
Olschewski M 1
Orr RK 71

Pai S 229
Pasqualini JR 139
Pelosi G 221
Piubello Q 221
Planting ASTh 183
Pollard CW 245

Quin RJ 245

Rainer H 213
Rauschecker HF 1
Remvikos Y 25
Rodella S 221

Sattler W 199
Sauer R 1
Sauerbrei W 1,279
Schauer A 1
Schmoor C 1
Schumacher M 1
Seegenschmiedt MH 1
Seguí MA 15
Seidell JC 55,129
Simonitsch I 213
Solà C 15
Soubeyran I 119
Sperotto L 221
Steger GG 213
Stoter G 183
Stranzl A 199
Suzuki N 35

Tabernero JM 15
Taylor JA 265
Terada S 35
Trojani M 119
Turazza M 221

Uchide K 35

van Dongen JA 77
van Leeuwen FE 77
van Ooijen B 77
Verweij J 183
Vicario G 237

Wafflart J 119
Ward BG 245
Warlamides E 213
Wechter R 45
Wei L 45
Welshons WV 265

Yan X 147
Yu X 229

Zaloznik AJ 195
Zoli W 63

Breast Cancer Research and Treatment **34**: 291-294, 1995.

Subject index, Volume 34

17β-hydroxysteroid dehydrogenase
effects of MPA and the antiestrogen EM-219, in rat DMBA mammary tumors 147-159
17β-hydroxysteroid dehydrogenase
estrone-estradiol conversion favored in estrogen-dependent cells, inhibited by antiestrogen ICI 164,384 139-146

Adriamycin
see doxorubicin
age at diagnosis
vs. associations of prognostic factors (S-phase, ploidy, steroid receptors, grade) 25-33
androgen receptor
genetic loss and breast cancer 176
animal models
rat mammary tumors induced by intraductal DMBA 35-43
antiestrogens
EM-219 and medroxyprogesterone acetate inhibit rat DMBA tumors 147-159
estrone-estradiol conversion favored in estrogen-dependent cells, inhibited by antiestrogen ICI 164,384 139-146

body fat distribution
see fat distribution
BRCA1 breast cancer gene
in familial breast cancer — review 171-183
breast cancer genes
review 171-183
breast preservation
vs. mastectomy — 4 year German trial 1-13
breast tumor progression
identical erbB-2 and DNA content in DCIS and invasive phases in the same breast 253-263

cell proliferation
phosphoinositide pathway involved in estrogen, not lithium or EGF, growth stimulation 265-277
chemotherapy
CAF vs. CNF (mitoxantrone combination) for metastatic breast cancer 15-24
cutaneous reactions to rhGM-CSF 213-219
long-term low-dose oral etoposide 183-189
taxol or taxotere more active than doxorubicin or cisplatin in primary breast cancer cells *in vitro* 63-69
cisplatin
taxol or taxotere more active than doxorubicin or cisplatin in primary breast cancer cells *in vitro* 63-69
clonogenic assay
taxol or taxotere more active than doxorubicin or cisplatin on primary breast cancer cells 63-69
colony stimulating factors (CSFs)
cutaneous reactions 213-219
cytokeratins
low sensitivity of TPS (as well as mucin-based antigens) as serum markers 245-251

diagnosis
low sensitivities of mucins (CA15-3, CASA, and MSA) and cytokeratins (TPS) as serum markers 245-251
DNA ploidy
age-dependent correlations (S-phase, ploidy, steroid receptors, grade) 25-33
identical erbB-2 and DNA content in DCIS and invasive phases in the same breast 253-263
doxorubicin
CAF vs. CNF (mitoxantrone combination) for metastatic breast cancer 15-24
taxol or taxotere more active than doxorubicin or cisplatin in primary breast cancer cells *in vitro* 63-69
ductal carcinoma in situ (DCIS)
identical erbB-2 and DNA content in DCIS and invasive phases in the same breast 253-263

ductal carcinomas
induced by intraductal DMBA in Wistar rats 35-43

elderly patients
tamoxifen as sole primary treatment? 77-83
endocrine therapy
somatostatin analogue (Lanreotide) 237-244
tamoxifen as sole primary treatment for elderly patients? 77-83
epidermal growth factor (EGF)
phosphoinositide pathway involved in estrogen, not lithium or EGF, growth stimulation 265-277
*erb*B-2
identical *erb*B-2 and DNA content in DCIS and invasive phases in the same breast 253-263
c-*erb*B-2 transfection reduces estrogen dependence of MCF-7 cell growth and tumor formation 97-117
estrogen
phosphoinositide pathway involved in estrogen, not lithium or EGF, growth stimulation 265-277
estrogen dependence
partially overcome by c-*erb*B-2 transfection in MCF-7 cells 97-117
estrogen metabolism
estrone-estradiol conversion favored in estrogen-dependent cells, inhibited by antiestrogen ICI 164,384 139-146
estrogen receptor
age-dependent correlations (S-phase, ploidy, steroid receptors, grade) 25-33
IHC vs. DCC assay correlation 221-228
ethnicity
see race
etoposide
long-term low-dose oral regimen 183-189

familial breast cancer
and breast cancer genes — review 171-183
fat distribution
no effect on breast cancer survival 129-137
vs. breast cancer risk 55-61
fatty acids
and serum apolipoproteins, in women with malignant or benign breast masses 161-169
polyunsaturated, in growth inhibition of breast cancer cell lines 199-212
flow cytometry
age-dependent correlations (S-phase, ploidy, steroid receptors, grade) 25-33

genetics
breast cancer genes — review 171-183
Grb2 protein
and Ras activation in breast cancer 85-92
Grb7 protein
association with c-ErbB-2 in breast cancer 85-92
growth hormone
failure of suppression in Lanreotide pilot study 237-244

HER-2/*neu*
*see erb*B-2
histopathologic grade
age-dependent correlations (S-phase, ploidy, steroid receptors, grade) 25-33

IGF-1
failure of suppression in Lanreotide pilot study 237-244
image analysis
identical *erb*B-2 and DNA content in DCIS and invasive phases in the same breast 253-263
immune phenomena
cutaneous reactions to rhGM-CSF 213-219
immunohistochemistry
IHC vs. DCC assays for estrogen receptor 221-228
pS2 in 942 patients — no multivariate prognostic significance 119-128
vasopressin and oxytocin related markers in breast tumors 229-235
intraductal carcinoma
see ductal carcinoma in situ

lipid hydroperoxides
in growth inhibition by polyunsaturated fatty acids 199-212
lithium
phosphoinositide pathway involved in estrogen, not lithium or EGF, growth stimulation 265-277

loss of heterozygosity (LOH)
and breast cancer genes — review 171-183

mastectomy
vs. breast preservation — 4 year German trial 1-13
MCF-7 cells
c-*erb*B-2 transfection reduces estrogen dependence 97-117
phosphoinositide pathway involved in growth stimulation by estrogen, not lithium or EGF 265-277
medroxyprogesterone acetate (MPA)
and the antiestrogen EM-219 inhibit rat DMBA mammary tumors 147-159
menstrual cycle
no effect of timing of breast surgery 279-287
mitoxantrone
CNF vs. CAF for metastatic breast cancer 15-24
mucins
low sensitivities of CA15-3, CASA, and MSA (and cytokeratin-based TPS) as serum markers 245-251

nodal status
positive nodes associated with increasing parity 71-76

obesity
body fat distribution vs. breast cancer risk 55-61
no effect on breast cancer survival 129-137
ornithine decarboxylase
MCF-7 stimulation and putrescine increase by over-expression (transfection) 45-53
oxytocin gene related proteins
immunohistochemical detection in breast cancers 229-235

p53 gene
alterations in familial vs. sporadic breast cancer 171-183
parity
positive nodes associated with increasing parity 71-76
peroxidation
lipid hydroperoxides in growth inhibition by polyunsaturated fatty acids 199-212
phospholipase C
as an SH2 domain protein in signal transduction 85-92
in phosphoinositide signalling pathway — stimulated by estrogen, not lithium or EGF 265-277
polyamines
MCF-7 stimulation by over-expressed (transfected) ornithine decarboxylase 45-53
polyunsaturated fatty acids
growth inhibition of breast cancer cell lines 199-212
progesterone receptor
age-dependent correlations (S-phase, ploidy, steroid receptors, grade) 25-33
prognostic factors
age-dependent correlations (S-phase, ploidy, steroid receptors, grade) 25-33
apolipoprotein ratios 161-169
IHC vs. DCC assays for estrogen receptor 221-228
nodal status — positive nodes associated with increasing parity 71-76
obesity, body fat distribution, without effect on breast cancer survival 129-137
pS2 in 942 patients — no multivariate significance 119-128
pS2
by immunohistochemistry in 942 patients — no multivariate prognostic significance 119-128

race
black vs. white stage at diagnosis (DOD health system) 195-198
Ras signalling
involvement of SH2 domain proteins (Grb2, Grb7, c-Src) 85-92
rat mammary tumors
antiestrogen EM-219 and medroxyprogesterone acetate inhibit rat DMBA tumors 147-159
induced by intraductal DMBA in Wistar rats 35-43
receptor tyrosine kinases
association with SH2 domain proteins in signal transduction — review 85-92
risk factors
body fat distribution 55-61

S-phase
age-dependent correlations (S-phase, ploidy, steroid receptors, grade) 25-33
Scarff-Bloom-Richardson
see histopathologic grade
serum lipids
and apolipoproteins, in women with malignant or benign breast masses 161-169
serum markers
mucin-based CA15-3, CASA, and MSA vs. cytokeratin-based TPS assays 245-251
SH2 domain-containing proteins
and signal transduction from receptor tyrosine kinases — review 85-92
signalling pathways
phosphoinositide pathway not involved in lithium or EGF growth stimulation 265-277
SH2 domain-containing proteins — review 85-92
socioeconomic status
black vs. white stage at diagnosis (DOD health system) 195-198
somatostatin analogues
failure of GH and IGF-1 suppression in Lanreotide pilot study 237-244
Src protein
as an SH2 domain protein, and possible role in breast cancer 85-92
surgery
breast preservation vs. mastectomy — 4 year German trial 1-13
surgery, timing
no effect of menstrual cycle 279-287

tamoxifen
as sole primary treatment for elderly patients? 77-83
taxanes
taxol or taxotere more active than doxorubicin or cisplatin in primary breast cancer cells *in vitro* 63-69
tumor size
black vs. white stage at diagnosis (DOD health system) 195-198
tyrosine kinases
association with SH2 domain proteins in signal transduction — review 85-92

vasopressin gene related proteins
selective feature of breast cancers 229-235
vitamin E
restoration of growth inhibited by polyunsaturated fatty acids 199-212